Danish firm QuantiBact has published a paper describing how its twisted intercalating nucleic acid, or TINA, molecule technology can be used to modify PCR primers to increase the efficiency, specificity, and sensitivity of quantitative and multiplex endpoint PCR assays.

With the publication, the company is hoping to build interest among life science research tool manufacturers and diagnostics companies, with whom QuantiBact is currently negotiating partnerships and potential licensing agreements around the technology, a company official said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.